VRTX - Vertex Pharmaceuticals Incorporated

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
188.07
+2.35 (+1.27%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close185.72
Open185.67
Bid183.00 x 800
Ask190.00 x 1200
Day's Range185.78 - 188.56
52 Week Range144.07 - 195.81
Volume1,408,240
Avg. Volume1,497,069
Market Cap48.081B
Beta (3Y Monthly)1.22
PE Ratio (TTM)23.25
EPS (TTM)8.09
Earnings DateApr 24, 2019 - Apr 29, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est207.53
Trade prices are not sourced from all markets
  • Business Wire3 days ago

    Positive Phase 3 Study for Tezacaftor/Ivacaftor Combination in Children Aged 6-11 Years with Cystic Fibrosis Supports European Medicines Agency Submission

    Vertex Pharmaceuticals Incorporated (VRTX) today announced the results of a Phase 3 study conducted in Europe and Australia of tezacaftor in combination with ivacaftor in children aged 6 through 11 years with cystic fibrosis (CF) who have either two copies of the F508del mutation or one copy of the F508del mutation and one residual function mutation. The study met its primary endpoint of absolute change in lung clearance index (LCI2.5) through 8 weeks of treatment, demonstrating a statistically significant improvement in LCI2.5 among patients treated with tezacaftor/ivacaftor.

  • GuruFocus.com3 days ago

    Vertex Pharmaceuticals Inc (VRTX) CEO & President Jeffrey M Leiden Sold $20.1 million of Shares

    CEO & President of Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Jeffrey M Leiden sold 111,431 shares of VRTX on 02/11/2019 at an average price of $180.24 a share.

  • Have Insiders Been Selling Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares?
    Simply Wall St.3 days ago

    Have Insiders Been Selling Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! It is not uncommon to see companiesRead More...

  • Groupon (GRPN) to Report Q4 Earnings: What's in the Cards?
    Zacks6 days ago

    Groupon (GRPN) to Report Q4 Earnings: What's in the Cards?

    Groupon (GRPN) rides on partnership with Grubhub along with ongoing brand awareness programs. Further, launching new products on a regular basis is a positive.

  • This Is the Best Biotech Stock on the Market
    Motley Fool7 days ago

    This Is the Best Biotech Stock on the Market

    Fantastic growth with more on the way. An attractive valuation. This biotech stock has it all.

  • Check Out These 7 Fast-Growing Stocks to Buy Today
    InvestorPlace8 days ago

    Check Out These 7 Fast-Growing Stocks to Buy Today

    Editor's note: This story was previously published in October 2018. It has since been updated and republished.The benefit of fast-growing stocks is self-evident, but as inflation becaomes something to start worrying about, fast-growing stocks have an importance tied to timing. If you haven't noticed, there has been a lot of talk about something that we haven't heard about for almost a decade, inflation.For nearly a decade, the Federal Reserve and all the central banks in all the industrialized nations have been managing interest rates to keep them outrageously low until the financial system had a chance to right itself.InvestorPlace - Stock Market News, Stock Advice & Trading TipsNow, we're in the next phase of that great experiment. Economies are coming back online and central banks are raising interest rates to keep inflation a bay while not shutting off the green shoots of growth.But this isn't a science. It's a bit messy. It means that growth will be more uneven than it has been in the past. You need to find firms with solid sales earnings growth as well as technical and fundamental strengths to keep the profits rolling. * 7 Reasons You Want Boeing Stock in Your Portfolio These are seven fast-growing stocks to buy today that will keep you in good stead for years to come. Kronos Worldwide (KRO)Kronos Worldwide, Inc. (NYSE: KRO) has a $2 billion market cap and is a very focused firm. It produces titanium dioxide (TiO2). The thing is, TiO2 has a very practical purpose that is used in a number of industries; it provides whiteness, brightness and opacity.As one of the leading providers of TiO2 in Europe and the U.S., its product is used in paints, coloring agents, plastics, rubber, silicone, ceramics, glass, the list goes on. It's a basic building block for an enormous amount of industrial and commercial applications.And as growth resumes and more products are sold, KRO will benefit by supplying a key ingredient to many of those products.Besides being one of our favorite a fast-growing stocks KRO also hands out a 4.12% dividend and trades a sub-8 price-earnings ratio.Source: Shutterstock Sherwin-Williams (SHW)Sherwin-Williams Co (NYSE:SHW) has sold paint and coatings now for 152 years. That's a pretty impressive record. But it's a bit unusual to see a paint company in a list of top growth stocks. Usually, it's some cloud storage firm or a breakout online retailer.However, SHW, by its size and reputation, has not only endured but it has positioned itself on top of the coatings heap. It grew from annual sales of $400,000 in 1866 to annual sales topping $15 billion last year, coming from over 100 countries around the world. * 10 Monster Growth Stocks to Buy for 2019 and Beyond Its size, scope and quality is one reason hardware giant Lowe's Companies, Inc. (NYSE:LOW) just inked a deal to be the only nationwide home seller to offer SHW products. This is even more exciting given that housing demand is back on track and the interest in homeowners to fixing up their current houses.Source: Shutterstock Vertex (VRTX)Vertex Pharmaceuticals (NASDAQ:VRTX) is one of the leading pharmaceuticals firms when it comes to treating cystic fibrosis (CF). That may not seem like much of a franchise given all the other more compelling diseases out there, but VRTX has built a $41 billion market cap in the sector and most of its competitors are looking for other places to find an opening.That is a big deal for pharma companies that usually are strong until patents run down or generics start eating into margins.Not so with VRTX. As new approvals keep rolling in for next-generation CF drugs, it has plenty more in the pipeline to keep this growth going.Source: Mike Mozart via Flickr Valero Energy (VLO)Valero Energy Corporation (NYSE:VLO) is one of the top refiners in the U.S. It now has 15 oil refineries which supply 3.1 million barrels per day, and its 11 ethanol plants deliver 1.4 billion gallons of ethanol per year. Its operations now stretch across the U.S., Canada, the U.K. and Ireland.When the economy is in a growth phase, refineries are a great place to have your money. They are one of the leading economic indicators since demand for fuel is a key sign more the economy is coming back. More demand for fuel means there's more transportation of goods and services. * The 9 Best Stocks to Invest In During a Manic Market There's no doubt that refining is as cyclical as most parts of the energy sector, but when times are good, they're very good. And times are getting better every day in the energy patch.Source: Mike Mozart via Flickr Royal Dutch Shell (RDS.A)Royal Dutch Shell (NYSE:RDS.A, NYSE:RDS.B) is one of the biggest players in the global energy markets. With a $300 billion market cap, the only Big Oil that's bigger is Exxon Mobil (NYSE:XOM). It's what is called an integrated energy company because it has operations from the fields to the pipelines to the refineries to the distribution.As with all energy firms, when times are bad, the more exposure you have to the entire production and distribution process, the tougher things get. But at the size the big oils are, they have the money to wait out the bad patches.And that's just what RDS.A has done. Now it's time to cash in. What's more, RDS.A is still delivering a mouth-watering 7.4% dividend, but that may wane as the stock price starts rising. In the meanwhile, it's easy to see why this is one of our picks for the best fast-growing stocks. Lumentum (LITE)Lumentum Holdings Inc (NASDAQ: LITE) is a specialty company that focuses on laser beams. It's one of the biggest optical and photonics companies in the world that is working on the 3D sensing sector.Essentially, 3D sensing is basically the gesture sensing that we all have become accustomed with in our mobile devices, screens in our cars, etc. It is one of the most ubiquitous aspects of our interactive age and one of the key parts of the Internet of Things (IoT) concept. * 10 F-Rated Stocks That Could Break Your Portfolio What's more, LITE is also a major player in the optical networking space that makes the infrastructure that makes our world "smarter," operating in as close to real time as possible. It's crucial for the next generation of cloud computing and network operations.Its laser division helps build the next generation of equipment that makes all this possible.Source: David Guo via Flickr Knight-Swift (KNX)Knight-Swift Transportation Holdings Inc (NYSE:KNX) had its humble beginnings in 1966, taking steel from the Port of Los Angeles to Arizona and bringing cotton from Arizona to LA.Today, KNX is a $5.8 billion business with 20,000 trucks on the road throughout the U.S. and Mexico. If you see a Swift logo on a truck while driving, it's a KNX truck.Charles Dow, the inspiration for the Dow Jones Industrial Average, also inspired a fundamental theory about the economy and the markets. It's simply called Dow Theory.One of the core tenants is that if you look at the transportation and the industrial sectors, you can predict how well the economy will be doing in the near future. If the transport business is rising, that's a bullish sign that the economy is on an upswing and KNX stock with it.Louis Navellier is a renowned growth investor. He is the editor of five investing newsletters: Blue Chip Growth, Emerging Growth, Ultimate Growth, Family Trust and Platinum Growth. His most popular service, Blue Chip Growth, has a track record of beating the market 3:1 over the last 14 years. He uses a combination of quantitative and fundamental analysis to identify market-beating stocks. Mr. Navellier has made his proven formula accessible to investors via his free, online stock rating tool, PortfolioGrader.com. Louis Navellier may hold some of the aforementioned securities in one or more of his newsletters.Compare Brokers The post Check Out These 7 Fast-Growing Stocks to Buy Today appeared first on InvestorPlace.

  • Markit9 days ago

    See what the IHS Markit Score report has to say about Vertex Pharmaceuticals Inc.

    Vertex Pharmaceuticals Inc NASDAQ/NGS:VRTXView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for VRTX with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting VRTX. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding VRTX totaled $16.13 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Factors Likely to Influence Cisco's (CSCO) Earnings in Q2
    Zacks9 days ago

    Factors Likely to Influence Cisco's (CSCO) Earnings in Q2

    Cisco (CSCO) to benefit from acquisition synergies and strength in the it's Security and Applications segments.

  • Factors Expected to Influence Akamai's (AKAM) Q4 Earnings
    Zacks9 days ago

    Factors Expected to Influence Akamai's (AKAM) Q4 Earnings

    Akamai (AKAM) benefits from the robust performance of security products and growth in Media and Carrier Division.

  • Vertex Pharmaceuticals: New Drug, Same Great Growth Story
    Motley Fool9 days ago

    Vertex Pharmaceuticals: New Drug, Same Great Growth Story

    The biotech continues to make inroads in cystic fibrosis.

  • The Zacks Analyst Blog Highlights: Gilead, Vertex, Celgene, Alkermes and AVEO
    Zacks10 days ago

    The Zacks Analyst Blog Highlights: Gilead, Vertex, Celgene, Alkermes and AVEO

    The Zacks Analyst Blog Highlights: Gilead, Vertex, Celgene, Alkermes and AVEO

  • GuruFocus.com10 days ago

    Vertex Pharmaceuticals Inc (VRTX) CEO & President Jeffrey M Leiden Sold $6 million of Shares

    CEO & President of Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Jeffrey M Leiden sold 32,250 shares of VRTX on 02/04/2019 at an average price of $186.35 a share.

  • Vertex (VRTX) Q4 Earnings Beat on Solid CF Products Sales
    Zacks11 days ago

    Vertex (VRTX) Q4 Earnings Beat on Solid CF Products Sales

    Vertex's (VRTX) Q4 grows on earnings and revenue beat with rising demand for its CF products. Shares up.

  • Stocks Turn Lower, But These Top Stocks Break Out On Earnings
    Investor's Business Daily11 days ago

    Stocks Turn Lower, But These Top Stocks Break Out On Earnings

    The stock market was modestly lower in morning trade Wednesday. Dow Jones stock Disney is nearing an entry, while IBD 50 stock Paycom surged higher.

  • Benzinga11 days ago

    The Daily Biotech Pulse: Paratek Launches Antibiotic In US, Eli Lilly Earnings, Catabasis Offering

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 5) Amphastar Pharmaceuticals Inc (NASDAQ: AMPH ) Array ...

  • Vertex Pharmaceuticals (VRTX) Q4 2018 Earnings Conference Call Transcript
    Motley Fool11 days ago

    Vertex Pharmaceuticals (VRTX) Q4 2018 Earnings Conference Call Transcript

    VRTX earnings call for the period ending December 31, 2018.

  • Dow Jones Futures: Snap Soars, But These 4 Top Stocks Are Crossing Buy Points
    Investor's Business Daily11 days ago

    Dow Jones Futures: Snap Soars, But These 4 Top Stocks Are Crossing Buy Points

    Yes, Snap soared late on Q4 results, but it's better to focus on top stocks near buys. Paycom, Vertex Pharmaceuticals, Tableau and Spirit Airlines crossed above or below buy points on earnings.

  • Biotech Stock Roundup: Celgene Tops in Q4, Gilead Disappoints, ALKS & AVEO Sink
    Zacks11 days ago

    Biotech Stock Roundup: Celgene Tops in Q4, Gilead Disappoints, ALKS & AVEO Sink

    Key highlights of the week were the fourth-quarter results by biotech bigwigs Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX) and Celgene (CELG).

  • Vertex Pharmaceuticals (VRTX) Q4 Earnings and Revenues Top Estimates
    Zacks11 days ago

    Vertex Pharmaceuticals (VRTX) Q4 Earnings and Revenues Top Estimates

    Vertex (VRTX) delivered earnings and revenue surprises of 23.81% and 6.27%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

  • This Key Biotech Franchise Tacked On 40% Growth In Fourth-Quarter Sales
    Investor's Business Daily11 days ago

    This Key Biotech Franchise Tacked On 40% Growth In Fourth-Quarter Sales

    Late Tuesday, Vertex Pharmaceuticals topped fourth-quarter sales and earnings forecasts as sales from the biotech's cystic fibrosis drugs rose by 40%. Vertex stock lifted in late action.

  • Associated Press11 days ago

    Vertex: 4Q Earnings Snapshot

    On a per-share basis, the Boston-based company said it had net income of $5.97. Earnings, adjusted for one-time gains and costs, came to $1.30 per share. The results topped Wall Street expectations. The ...

  • Business Wire11 days ago

    Vertex Reports Full-Year and Fourth-Quarter 2018 Financial Results

    - Full-year 2018 CF product revenues of $3.04 billion, a 40% increase compared to $2.17 billion in 2017; fourth-quarter 2018 CF product revenues of $868 million -

  • ACCESSWIRE11 days ago

    Vertex Pharmaceuticals Incorporated to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / February 5, 2019 / Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February ...

  • Investing.com11 days ago

    Vertex Earnings, Revenue beat in Q4

    Investing.com - Vertex (NASDAQ:VRTX) reported fourth quarter earnings that beat analysts' expectations on Tuesday and revenue that topped forecasts.

  • Regeneron (REGN) to Report Q4 Earnings: Is a Beat in Store?
    Zacks13 days ago

    Regeneron (REGN) to Report Q4 Earnings: Is a Beat in Store?

    Strong Eylea and Dupixent sales are likely to propel better-than-expected results for Regeneron (REGN) when it reports fourth-quarter results.